Amgen has submiited its Humira biosimilar for regulatory review in what it believes is the first challenge to AbbVie's blockbuster biologic in the US.
The UK and Japan plan to work together on breaking into each other’s markets with regenerative medicines.
Watson-Marlow Fluid Technologies has bought Flow Smart for £5.7m ($5.3m) to bolster its biopharma-focused pump and fluid path tech portfolio.
University College London is forming a spin-out gene therapy company to develop large molecule treatments for eye disease.
Preclinical CRO Biopta will add stem cell programming tech to its offering, expand in Japan and nearly double its workforce under new owner, Reprocell.
Ablynx has licensed its nanobody platform to Novo Nordisk which hopes to discover and develop single-domain antibody fragment drug candidates.